TY - JOUR
T1 - Novel laboratory tests in assessment of liver function in cute and chronic liver diseases
AU - Viksna, Ludmila
AU - Keišs, Jāzeps
AU - Sočņevs, Arturs
AU - Rozentale, Baiba
AU - Pilmane, Mara
AU - Sevastjanova, Natalija
AU - Buiķe, Inita
AU - Jeruma, Agita
AU - Eglite, Elena
AU - Ābeltiņa, Kristīne
AU - Sondore, Valentīna
N1 - Funding Information:
The work was supported by the National Research Programme in Medicine 2006–2009 project No. 10. „Blood-transmissive viral infections affecting life expectancy: viral persistence in human organism and paradigms of diagnostics and treatment”.
PY - 2009
Y1 - 2009
N2 - Liver biopsy in clinical practice has been widely used for the diagnosis and management of patients with liver diseases, particularly, with chronic liver diseases. However, liver biopsy is an invasive method with potential complications, sampling and interpretation errors. Therefore, noninvasive tests are being developed and introduced to replace liver biopsy. The aim of the present study was to identify the new noninvasive methods to be used for the assessment of liver structure and function, by use of the appropriate serum surrogate markers and to evaluate the clinical diagnostic and prognostic accuracy of these methods, including immunogenetic methods, in cases of acute and chronic liver diseases. The obtained data showed that serum markers of apoptosis (cytokeratin-18 neoepitope and citochrome c) and fibrosis (hyaluronic acid) should be included in viral and toxic liver damage management algorithms. The punctual identification of immunogenetic factors (HLA class II antigens) may prove to be useful in predicting disease evolution, and in guiding the appropriate therapy for patients with poor prognosis.
AB - Liver biopsy in clinical practice has been widely used for the diagnosis and management of patients with liver diseases, particularly, with chronic liver diseases. However, liver biopsy is an invasive method with potential complications, sampling and interpretation errors. Therefore, noninvasive tests are being developed and introduced to replace liver biopsy. The aim of the present study was to identify the new noninvasive methods to be used for the assessment of liver structure and function, by use of the appropriate serum surrogate markers and to evaluate the clinical diagnostic and prognostic accuracy of these methods, including immunogenetic methods, in cases of acute and chronic liver diseases. The obtained data showed that serum markers of apoptosis (cytokeratin-18 neoepitope and citochrome c) and fibrosis (hyaluronic acid) should be included in viral and toxic liver damage management algorithms. The punctual identification of immunogenetic factors (HLA class II antigens) may prove to be useful in predicting disease evolution, and in guiding the appropriate therapy for patients with poor prognosis.
KW - Apoptosis fibrosis
KW - HLA class II antigens
KW - Liver diseases
UR - http://www.scopus.com/inward/record.url?scp=73349122298&partnerID=8YFLogxK
U2 - 10.2478/v10046-009-0035-4
DO - 10.2478/v10046-009-0035-4
M3 - Article
AN - SCOPUS:73349122298
SN - 1407-009X
VL - 63
SP - 228
EP - 233
JO - Proceedings of the Latvian Academy of Sciences, Section B: Natural, Exact, and Applied Sciences
JF - Proceedings of the Latvian Academy of Sciences, Section B: Natural, Exact, and Applied Sciences
IS - 4-5
ER -